Beam Therapeutics (BEAM) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAM shares.
View BEAM analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12-month target prices for Beam Therapeutics' shares. Their BEAM share price forecasts range from $37.00 to $105.00. On average, they predict the company's share price to reach $67.91 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.
View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts.

Beam Therapeutics' stock was trading at $39.11 on January 1st, 2023. Since then, BEAM stock has decreased by 14.5% and is now trading at $33.45.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BEAM earnings forecast.

Beam Therapeutics Inc. (NASDAQ:BEAM) released its earnings results on Wednesday, May, 10th. The company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.03. The company had revenue of $24.21 million for the quarter, compared to analyst estimates of $14.41 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 42.04% and a negative net margin of 412.45%.

ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and SPDR S&P Biotech ETF (XBI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Beam Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.84%), FMR LLC (8.15%), BlackRock Inc. (7.08%), Temasek Holdings Private Ltd (5.48%), Farallon Capital Management LLC (4.60%) and State Street Corp (4.25%). Insiders that own company stock include Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends.

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BEAM stock can currently be purchased for approximately $33.45.

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $2.55 billion and generates $60.92 million in revenue each year. The company earns $-289,090,000.00 in net income (profit) each year or ($4.45) on an earnings per share basis.

The company employs 341 workers across the globe.

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com.